Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

Inclusion Criteria: * Participant of either gender aged ≥50 years * Positive history of varicella or residence for \>30 years in a country with endemic VZV infection * All females must be postmenopausal or have a negative serum or urine pregnancy test or acceptable method of birth control for three months after vaccination * Participant having signed the informed consent form prior to any study procedure Exclusion Criteria: * Febrile within 72 hours prior to vaccination * Prior history of Herpes Zoster clinically diagnosed by a physician * Previously received a varicella or zoster vaccine * Exposure to varicella or herpes-zoster within 4 weeks prior to vaccination * Received any other live virus vaccine within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study * Received any inactivated vaccine within 2 weeks prior to vaccination, or is expected to receive any inactivated vaccine during the study * Was treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or is expected to be treated during the study * Taking any non topical antiviral therapy with activity against herpesviruses. * On immunosuppressive therapy * Known or suspected immune dysfunction caused by a medical condition, or any other cause * History of hypersensitivity reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin * Known active tuberculosis * Significant underlying illness preventing completion of the study